enGene Therapeutics ENGN
NASDAQ ENGN
$1.78 +0.01 (+0.56%)
At close: Aug 21, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Change in Acquisitions & Divestments (2025 - 2026)

enGene Therapeutics (ENGN) posted quarterly Change in Acquisitions & Divestments of $74.0 million for Q2 2026, up 132.91% year-over-year from $31.8 million in Q2 2025, and up 71.8% quarter-over-quarter from $43.0 million in Q1 2026.

enGene Therapeutics (ENGN) Change in Acquisitions & Divestments (2025 - 2026) Analysis & Trends

enGene Therapeutics (ENGN) has reported Change in Acquisitions & Divestments for 2 consecutive years, with $74.0 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Change in Acquisitions & Divestments rose 132.91% year-over-year to $74.0 million; the TTM figure through Apr 2026 stood at $212.4 million (changed N/A YoY), while the FY2025 annual figure was $137.2 million, changed N/A from the prior year.
  • Change in Acquisitions & Divestments rose to $74.0 million in Q2 2026 per ENGN's latest filing, from $43.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $74.0 million in Q2 2026 and bottomed at $10.0 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 enGene Therapeutics 124.11 Mn 124.11 Mn -

Historic Data

Download Data
DateValue
Apr 30, 2026 73.95 Mn
Apr 30, 2026 73.95 Mn
Jan 31, 2026 43.04 Mn
Jan 31, 2026 43.04 Mn
Oct 31, 2025 48.69 Mn
Oct 31, 2025 48.69 Mn
Jul 31, 2025 46.76 Mn
Jul 31, 2025 46.76 Mn
Apr 30, 2025 31.75 Mn
Apr 30, 2025 31.75 Mn
Jan 31, 2025 10.00 Mn
Jan 31, 2025 10.00 Mn